United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Vectus Biosystems (ASX:VBS) exits VB4-P5—can this microcap regain momentum with VB0004? Vectus Biosystems signs US$3M deal to license VB4-P5 to XORTX. Can its lead fibrosis drug VB0004 now deliver the next big upside? byVenkateshOctober 18, 2025